# PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients

> **NCT00948090** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 207 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)

## Key facts

- **NCT ID:** NCT00948090
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2013-05
- **Final completion:** 2013-06
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2014-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00948090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00948090, "PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00948090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*